Invasive mucormycosis is a life-threatening fungal infection in immunocompromised children. It is associated with high mortality rates with limited data concerning the outcome in the pediatric population. Isavuconazole is the newest generation triazole approved for the treatment of invasive mucormycosis in adult patients, but clinical trials have not yet been performed in pediatric population although results of few cases report improvement following the initation of this treatment. We report a case of a 14-year old girl treated for acute lymphoblastic leukemia complicated by destructive necrotic fungal pneumonia and mycotic abscesses on her kidneys. The patient was treated successfully with surgical lobectomy of the inferior lobe of her left lung, nephrectomy and antifungal combination therapy (Amphotericin B and Isavuconazole). At the time of this report, three months after initatiating isavuconazole treatment, the patient continues to receive the drug daily and is doing well. Regarding side effects, we reported transient increase in blood urea and creatinine.
Despite the fact that the Isavuconazole offers new perspectives, further studies are necessary to confirm effectiveness in the pediatric population.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.